We are live on ! Find out more
VOR icon

Vor Biopharma
VOR

60 hedge funds and large institutions have $134M invested in Vor Biopharma in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

5% more capital invested

Capital invested by funds: $128M → $134M (+$6.84M)

2% more funds holding

Funds holding: 59 → 60 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.05% less ownership

Funds ownership: 4.46% → 4.41% (-0.05%)

Holders
60
Holders Change
+1
Holders Change %
+1.69%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
7
Increased
21
Reduced
14
Closed
5
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
MCM
MAI Capital Management
Ohio
+$737K
2
Morgan Stanley
Morgan Stanley
New York
+$551K
3
BlackRock
BlackRock
New York
+$298K
4
Northern Trust
Northern Trust
Illinois
+$94.5K
5
Barclays
Barclays
United Kingdom
+$92.6K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.34M
2
AG
Artal Group
Luxembourg
-$703K
3
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$317K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$66.5K
5
Squarepoint
Squarepoint
New York
-$33.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$51.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$17.1M -$66.5K -1,612 -0.4%
PBA
3
Paradigm Biocapital Advisors
New York
$14.5M -$8.58K -208 -0.1%
5VM
4
5AM Venture Management
California
$14.3M – – –
LCM
5
Laurion Capital Management
New York
$7.16M – – –
AG
6
Artal Group
Luxembourg
$5.28M -$703K -17,030 -13%
BlackRock
7
BlackRock
New York
$5.07M +$298K +7,228 +7%
Vanguard Group
8
Vanguard Group
Pennsylvania
$3.92M +$55.8K +1,351 +2%
WP
9
Woodline Partners
California
$2.5M – – –
JJ
10
Johnson & Johnson
New Jersey
$2.42M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.79M +$77.8K +1,885 +5%
SCM
12
Sarissa Capital Management
Connecticut
$1.39M – – –
State Street
13
State Street
Massachusetts
$1.37M +$4.33K +105 +0.3%
Northern Trust
14
Northern Trust
Illinois
$894K +$94.5K +2,289 +13%
MCM
15
MAI Capital Management
Ohio
$804K +$737K +17,858 New
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$779K – – –
Morgan Stanley
17
Morgan Stanley
New York
$774K +$551K +13,355 +347%
BCM
18
Bridgeway Capital Management
Texas
$366K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$243K – – –
Charles Schwab
20
Charles Schwab
California
$234K – – –
TOCUITCONY
21
Trustees of Columbia University in the City of New York
New York
$207K – – –
N
22
Nuveen
North Carolina
$161K – – –
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$143K +$22.2K +537 +20%
ETC
24
Exchange Traded Concepts
Oklahoma
$135K +$31.5K +763 +34%
BG
25
Bollard Group
Massachusetts
$125K – – –
1
2 3

VOR Hedge Fund Activity: Q4 2023 in Review

60 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2023, worth a combined $134M — up 5.4% from $128M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VOR positions and 5 closed out — a net gain of 2 holders — while 21 added to existing stakes and 14 trimmed.

The largest buyer was MAI Capital Management, opening a new position worth an estimated $737K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.34M sold.

  • 60 institutional investors held Vor Biopharma (VOR) as of Q4 2023, up from 59 in Q3 2023.
  • Funds reported $134M of Vor Biopharma stock for Q4 2023, up 5.4% quarter-over-quarter.
  • 7 funds opened new Vor Biopharma positions in Q4 2023 and 5 closed out, a net change of +2 holders.
  • The largest Vor Biopharma buyer in Q4 2023 was MAI Capital Management, an estimated $737K added.
  • The largest Vor Biopharma seller in Q4 2023 was Baker Bros. Advisors, an estimated $1.34M sold.

Based on aggregated 13F filings for Q4 2023.